Limitations of diabetes pharmacotherapy: results from the Vermont Diabetes Information System study.
about
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemAssociation of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information systemGlycemic Control Outcomes by Gender in the Pay-for-Performance System: A Retrospective Database Analysis in Patients with Type 2 Diabetes Mellitus.Predictors of initial levels and trajectories of anxiety in women before and for 6 months after breast cancer surgery.Trajectories of Depressive Symptoms in Women Prior to and for Six Months After Breast Cancer Surgery.Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery.Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery.Determination of cutpoints for low and high number of symptoms in patients with advanced cancer.Identification of patient subgroups and risk factors for persistent breast pain following breast cancer surgery.Co-occurrence of anxiety and depressive symptoms following breast cancer surgery and its impact on quality of lifeDifferences in depression, anxiety, and quality of life between women with and without breast pain prior to breast cancer surgery.Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery.Potassium Channel Candidate Genes Predict the Development of Secondary Lymphedema Following Breast Cancer Surgery.
P2860
Q33288486-29B70E1A-E0D4-4137-AE91-40F15E862A2FQ33390497-0FFA14D1-9EFB-4F65-8FC9-E560961A72E9Q34119263-1C11E68C-4036-475A-91A9-29B525F298BAQ34173880-916B55A7-C805-46F7-877B-14199A9B7E1BQ34463854-E51B5CC3-48D9-42E0-ADEC-D9A941821517Q34683635-830AAD67-7DA7-4D14-A10B-D56037A5E887Q35091181-DF3BA5DB-45BE-4AE7-8A12-67D6C0E3861DQ36172955-6C622BCC-ADAD-4DED-82BD-1FD3C96F6837Q36438840-2A9832D9-3E1B-4C5B-B401-4C5F048986F3Q36446745-A984B5A9-1080-4EEF-BD71-A638CCB3BF20Q36472876-E5F120C0-E8D6-4710-845A-7B0BC5FD9AF8Q37653735-39AA3E67-1A20-4536-B874-646F55FB6C06Q46796586-E79D89DB-AE3C-4D9A-B247-B6C5BF1DA36D
P2860
Limitations of diabetes pharmacotherapy: results from the Vermont Diabetes Information System study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Limitations of diabetes pharma ...... etes Information System study.
@ast
Limitations of diabetes pharma ...... etes Information System study.
@en
Limitations of diabetes pharma ...... etes Information System study.
@nl
type
label
Limitations of diabetes pharma ...... etes Information System study.
@ast
Limitations of diabetes pharma ...... etes Information System study.
@en
Limitations of diabetes pharma ...... etes Information System study.
@nl
prefLabel
Limitations of diabetes pharma ...... etes Information System study.
@ast
Limitations of diabetes pharma ...... etes Information System study.
@en
Limitations of diabetes pharma ...... etes Information System study.
@nl
P2860
P356
P1433
P1476
Limitations of diabetes pharma ...... etes Information System study.
@en
P2093
Amanda G Kennedy
Charles D MacLean
P2860
P2888
P356
10.1186/1471-2296-7-50
P577
2006-08-15T00:00:00Z
P5875
P6179
1012249007